Antimicrobial activity of PVP from an Antarctic bacterium, <i>Janthinobacterium</i> sp. Ant5-2, on multi-drug and methicillin resistant <i>Staphylococcus aureus</i>

doi:10.1007/s13659-012-0021-4

Natural Products and Bioprospecting

2012, Vol. 2

Issue (3) : 104-110 DOI: 10.1007/s13659-012-0021-4

Regular Article

Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

Jonathan P. HUANG^a, Nazia MOJIB^a,e, Rakesh R. GOLI^a, Samantha WATKINS^a, Ken B. WAITES^b, Rasik RAVINDRA^c, Dale T. ANDERSEN^d, Asim K. BEJ^a

a Department of Biology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
b Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
c National Centre for Antarctic & Ocean Research, Head Land Sada, Vasco-da-Gama Goa 403804, India;
d Carl Sagan Center for the Study of Life in the Universe, SETI Institute, Mountain View, CA 94043, USA;
e Red Sea Research Center, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

Abstract
References
Related Articles
Metrics

Download: PDF(960 KB) HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Multiple drug resistant(MDR) and methicillin-resistant Staphylococcus aureus(MRSA) have become increasingly prevalent as a community acquired infection. As a result limited treatment options are available with conventional synthetic antibiotics. Bioprospecting natural products with potent antimicrobial activity show promise for developing new drugs against this pathogen. In this study, we have investigated the antimicrobial activity of a purple violet pigment(PVP) from an Antarctic bacterium, Janthinobacterium sp. Ant5-2 on 15 clinical MDR and MRSA strains. The colorimetric resazurin assay was employed to determine the minimum inhibitory concentration(MIC₉₀) of PVP against MDR and MRSA. The MIC₉₀ ranged between 1.57 μg/mL and 3.13 μg/mL, which are significantly lower than many antimicrobials tested from natural sources against this pathogen. The spectrophotometrically determined growth analysis and total microscopic counts using Live/dead® BacLight^TM fluorescent stain exhibited a steady decrease in viability of both MDR and MRSA cultures following treatment with PVP at the MIC levels. In silico predictive molecular docking study revealed that PVP could be a DNA-targeting minor groove binding antimicrobial compound. The continued development of novel antimicrobials derived from natural sources with the combination of a suite of conventional antibiotics could stem the rising pandemic of MDR and MRSA along with other deadly microbial pathogens.

Keywords natural product bacterial pigment resazurin assay minimum inhibitory concentration(MIC)

Fund:We thank Col.(IL) J. N. Pritzker ARNG(Retired), Tawani Foundation(Chicago) for supporting the Tawani 2008 International Antarctic Scientific Expedition;Marty Kress, VCSI, Inc. /NASA;Richard Hoover, NASA;and 2008-2009 Antarctic Maitri(India) and Novolazarevskaya(Russia) Station staffs.

Issue Date: 11 February 2018

	Service

	E-mail this article
	E-mail Alert
	RSS
	Articles by authors

	Jonathan P. HUANG
	Nazia MOJIB
	Rakesh R. GOLI
	Samantha WATKINS
	Ken B. WAITES
	Rasik RAVINDRA
	Dale T. ANDERSEN
	Asim K. BEJ

Trendmd:

Cite this article:

Jonathan P. HUANG,Nazia MOJIB,Rakesh R. GOLI, et al. Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus[J]. Natural Products and Bioprospecting, 2012, 2(3): 104-110.

URL:

http://npb.kib.ac.cn/EN/10.1007/s13659-012-0021-4 OR http://npb.kib.ac.cn/EN/Y2012/V2/I3/104

[1]	Gould, I. M. J. Hosp. Infect. 2005, 61, 277-282.
[2]	Archer, G. L. Clin. Infect. Dis. 1998, 26, 1179-1181.
[3]	Hidayat, L. K.; Hsu, D. I.; Quist, R.; Shriner, K. A.; WongBeringer, A. Arch. Intern. Med. 2006, 166, 2138-2144.
[4]	Chambers, H. F. Emerg. Infect. Dis. 2001, 7, 178-182.
[5]	David, M. Z.; Daum, R. S. Clin. Microbiol. Rev. 2010, 23, 616-687.
[6]	Klein, E.; Smith, D. L.; Laxminarayan, R. Emerg. Infect. Dis. 2007, 13, 1840-1846.
[7]	Critchley, I. A.; Blosser-Middleton, R. S.; Jones, M. E.; Thornsberry, C.; Sahm, D. F.; Karlowsky, J. A. Antimicrob. Agents Chemother. 2003, 47, 1689-1693.
[8]	Ardic, N.; Ozyurt, M.; Sareyyupoglu, B.; Haznedaroglu, T. Int. J. Antimicrob. Agents 2005, 26, 213-218.
[9]	Frazee, B. W.; Lynn, J.; Charlebois, E. D.; Lambert, L.; Lowery, D.; Perdreau-Remington, F. Ann. Emerg. Med. 2005, 45, 311-320.
[10]	Kuroda, M. et al. Lancet 2001, 357, 1225-1240.
[11]	Enright, M. C.; Robinson, D. A.; Randle, G.; Feil, E. J.; Grundmann, H.; Spratt, B. G. Proc. Natl. Acad. Sci. USA 2002, 99, 7687-7692.
[12]	Clardy, J.; Fischbach, M. A.; Walsh, C. T. Nat. Biotechnol. 2006, 24, 1541-1550.
[13]	Brady, A.; Loughlin, R.; Gilpin, D.; Kearney, P.; Tunney, M. J. Med. Microbiol. 2006, 55, 1375-1380.
[14]	Obiang-Obounou, B. W.; Kang, O. H.; Choi, J. G.; Keum, J. H.; Kim, S. B.; Mun, S. H.; Shin, D. W.; Kim, K. W.; Park, C. B.; Kim, Y. G.; Han, S. H.; Kwon, D. Y. J. Toxicol. Sci. 2011, 36, 277-283.
[15]	Chung, P. Y.; Navaratnam, P.; Chung, L. Y. Ann. Clin. Microbiol. Antimicrob. 2011, 10, 25-31.
[16]	Yu, Y. Y.; Wang, H.; Zhang, S. W.; Wang, B. E. Chin. Med. J. 2010, 123, 1017-1020.
[17]	Pesewu, G. A.; Cutler, R. R.; Humber, D. P. J. Ethnopharmacol. 2008, 116, 102-111.
[18]	Molinski, T. F.; Faulkner, D. J. Tetrahedron Lett. 2001, 29, 2137-2138.
[19]	Lo Giudice, A.; Bruni, V.; Michaud, L. J. Basic Microbiol. 2007, 47, 496-505.
[20]	Mojib, N.; Philpott, R.; Huang, J. P.; Niederweis, M.; Bej, A. K. Antonie Van Leeuwenhoek 2010, 98, 531-540.
[21]	Desnottes, J. F. Trend Biotechnol. 1996, 14, 134-140.
[22]	Mojib, N.; Nasti, T. H.; Andersen, D. T.; Attigada, V. R.; Hoover, R. B.; Yusuf, N.; Bej, A. K. Int. J. Dermatol. 2011, 50, 1223-1233.
[23]	Anoopkumar-Dukie, S.; Carey, J. B.; Conere, T.; O'sullivan, E.; van Pelt, F. N.; Allshire, A. Br. J. Radiol. 2005, 78, 945-947.
[24]	Duarte, M.; Giordani, R. B.; De Carli, G. A.; Zuanazzi, J. A.; Macedo, A. J.; Tasca, T. Exp. Parasitol. 2009, 123, 195-198.
[25]	Martin, A.; Camacho, M.; Portaels, F.; Palomino, J. C. Antimicrob. Agents Chemother. 2003, 47, 3616-3619.
[26]	Martin, A.; Morcillo, N.; Lemus, D.; Montoro, E.; Telles, M. A.; Simboli, N.; Pontino, M.; Porras, T.; León, C.; Velasco, M.; Chacon, L.; Barrera, L.; Ritacco, V.; Portaels, F.; Palomino, J. C. Int. J. Tuberc. Lung Dis. 2005, 9, 901-906.
[27]	Rivoire, N.; Ravololonandriana, P.; Rasolonavalona, T.; Martin, A.; Portaels, F.; Ramarokoto, H.; Rasolofo Razanamparany, V. Int. J. Tuberc. Lung Dis. 2007, 11, 683-688.
[28]	Sanchez, J. G. B.; Kouzetsov, V. V. Braz. J. Microbiol. 2010, 41, 270-277.
[29]	Hsieh, P. C.; Siegel, S. A.; Rogers, B.; Davis, D.; Lewis, K. Proc. Natl. Acad. Sci. USA 1998, 95, 6602-6606.
[30]	Piddock, L. J. V. Clin. Microbiol. 2006, 19, 382-402.
[31]	Durai, R.; Ng, P. C.; Hoque, H. AORN. J. 2010, 91, 599-606.
[32]	Dharmaratne, H. R. W.; Wijesinghe, W. M. N. M.; Thevanasem, V. J. Ethnopharmacol. 1999, 66, 339-342.
[33]	Cutler, R. R.; Wilson, P. Br. J. Biomed. Sci. 2005, 61, 71-74.
[34]	Martins, D.; Costa, F. T. M.; Brocchi, M.; Duran, N. J. Nanopart. Res. 2011, 13, 355-363.
[35]	Mustaffa, F.; Indurkar, J.; Ismail, S.; Shah, M.; Mansor, S. M. Molecules 2011, 16, 3037-3047.
[36]	Vera, N.; Solorzano, E.; Ordonez, R.; Maldonado, L.; Bedascarrasbure, E.; Isla, M. I. Nat. Prod. Commun. 2011, 6, 823-827.
[37]	Choi, J. G.; Kang, O. H.; Lee, Y. S.; Oh, Y. C.; Chae, H. S.; Obiang-Obounou, B.; Park, S. C.; Shin, D. W.; Hwang, B. Y.; Kwon, D. Y. Eur. Rev. Med. Pharmacol. Sci. 2010, 14, 1005-1009.
[38]	Sianglum, W.; Srimanote, P.; Wonglumsom, W.; Kittiniyom, K.;Voravuthikunchai, S. P. PLoS One 2011, 6, e16628.
[39]	Chew, Y. L.; Chan, E. W.; Tan, P. L.; Lim, Y. Y.; Stanslas, J.; Goh, J. K. BMC Complement Altern. Med. 2011, 11, 12.
[40]	Jeong, S. I.; Kim, S. Y.; Kim, S. J.; Hwang, B. S.; Kwon, T. H.; Yu, K. Y.; Hang, S. H.; Suzuki, K.; Kim, K. J. Molecules 2010, 15, 7395-7402.
[41]	Mulyaningsih, S.; Youns, M.; El-Readi, M. Z.; Ashour, M. L.; Nibret, E.; Sporer, F.; Herrmann, F.; Reichling, J.; Wink, M. J. Pharm. Pharmacol. 2010, 62, 1037-1044.
[42]	Hannan, A.; Saleem, S.; Chaudhary, S.; Barkaat, M.; Arshad, M. U. J. Ayub. Med. Coll. Abbottabad. 2008, 20, 72-74.
[43]	Wang, G.; Hindler, J. F.; Ward, K. W.; Bruckner, D. A. J. Clin. Microbiol. 2006, 44, 3883-3886.
[44]	Nightingale, C. H.; Ambrose, P. G.; Drusano, G. L.; Murakawa, T. (eds.) Antimicrobial pharmacodynamics in theory and clinical practice (Infectious Disease and Therapy). Informa Heathcare:New York, 2nd ed. 2007; p 239-266.
[45]	Cenizal, M. J.; Skiest, D.; Luber, S.; Bedimo, R.; Davis, P.; Fox, P.; Delaney, K.; Hardy, R. D. Antimicrob. Agents Chemother. 2007, 51, 2628-2630.
[46]	Reeves, D. S.; Holt, H. A.; Phillips, I.; King, A.; Miles, R. S.; Paton, R.; Wise, R.; Andrews, J. M. J. Antimicrob. Chemother. 1991, 27, 469-474.
[47]	Wilson, A. P.; Cepeda, J. A.; Hayman, S.; Whitehouse, T.; Singer, M.; Bellingan, G. J. Antimicrob. Chemother. 2006, 58, 470-473.
[48]	Panchal, R. G.; Ulrich, R. L.; Lane, D.; Butler, M. M.; Houseweart, C.; Opperman, T.; Williams, J. D.; Peet, N. P.; Moir, D. T.; Nguyen, T.; Gussio, R.; Bowlin, T.; Bavari, S. Antimicrob. Agents Chemother. 2009, 53, 4283-4291.
[49]	Butler, M. M.; Williams, J. D.; Peet, N. P.; Moir, D. T.; Panchal, R. G.; Bavari, S.; Shinabarger, D. L.; Bowlin, T. L. Antimicrob. Agents Chemother. 2010, 54, 3974-3977.
[50]	Palchaudhuri, R.; Hergenrother, P. J. Curr. Opin. Biotechnol. 2007, 18, 497-503.
[51]	Chaires, J. B. Biopolymers 1997, 44, 201-215.
[52]	Ricci, C. G.; Netz, P. A. J. Chem. Inf. Model. 2009, 49, 1925-2935.
[53]	Martineau, F.; Picard, F. J.; Roy, P. H.; Ouellette, M.; Bergeron, M. G. J. Clin. Microbiol. 1998, 36, 618-623.
[54]	Reischl, U.; Linde, H. J.; Metz, M.; Leppmeier, B.; Lehn, N. J. Clin. Microbiol. 2000, 38, 2429-2433.
[55]	Shrestha, N. K.; Tuohy, M. J.; Hall, G. S.; Isada, C. M.; Procop, G. W. J. Clin. Microbiol. 2002, 40, 2659-2661.
[56]	Ausubel, F. M.; Brent, R.; Kingston, R. E.; Moore, D. D.; Smith, J. G.; Sideman, J. G.; Struhl, K. (eds.) Current protocols in molecular biology. John Wiley & Sons, Inc:New York, 1987.
[57]	Rettori, D.; Duran, N. World J. Microbiol. Biotechnol. 1998, 14, 685-688.
[58]	Sarker, S. D.; Nahar, L.; Kumarasamy, Y. Methods 2007, 42, 321-324.
[59]	Boulos, L.; Prévost, M.; Barbeau, B.; Coallier, J.; Desjardins, R. J. Microbiol. Methods 1999, 37, 77-86.
[60]	Auty, M. A.; Gardiner, G. E.; McBrearty, S. J.; O'Sullivan, E. O.; Mulvihill, D. M.; Collins, J. K.; Fitzgerald, G. F.; Stanton, C.; Ross, R. P. Appl. Environ. Microbiol. 2001, 67, 420-425.
[61]	Ritchie, D. W.; Venkatraman, V. Bioinformatics 2010, 26, 2398-2405.
[62]	Leite, T. B.; Gomes, D.; Miteva, M. A.; Chomilier, J.; Villoutreix, B. O.; Tuffery, P. Nucleic Acids Res. 2007, 35, W568-572.

[1]	Ai-Jun Ding, Shan-Qing Zheng, Xiao-Bing Huang, Ti-Kun Xing, Gui-Sheng Wu, Hua-Ying Sun, Shu-Hua Qi, Huai-Rong Luo. Current Perspective in the Discovery of Anti-aging Agents from Natural Products[J]. Natural Products and Bioprospecting, 2017, 7(5): 335-404.
[2]	Fidele Ntie-Kang, Leonel E. Njume, Yvette I. Malange, Stefan Günther, Wolfgang Sippl, Joseph N. Yong. The Chemistry and Biological Activities of Natural Products from Northern African Plant Families: From Taccaceae to Zygophyllaceae[J]. Natural Products and Bioprospecting, 2016, 6(2): 63-96.
[3]	Kun Wei, Gang-Qiang Wang, Xue Bai, Yan-Fen Niu, He-Ping Chen, Chun-Nan Wen, Zheng-Hui Li, Ze-Jun Dong, Zhi-Li Zuo, Wen-Yong Xiong, Ji-Kai Liu. Structure-Based Optimization and Biological Evaluation of Pancreatic Lipase Inhibitors as Novel Potential Antiobesity Agents[J]. Natural Products and Bioprospecting, 2015, 5(3): 129-157.
[4]	Frank Surup, Eric Kuhnert, Elena Liscinskij, Marc Stadler. *Silphiperfolene-Type Terpenoids and Other Metabolites from Cultures of the Tropical Ascomycete Hypoxylon rickii(Xylariaceae)*[J]. Natural Products and Bioprospecting, 2015, 5(3): 167-173.
[5]	Joel Heisler, Lindsay Elvir, Farah Barnouti, Erica Charles, Tom D. Wolkow, Radha Pyati. *Morphological Effects of Natural Products on Schizosaccharomyces pombe* Measured by Imaging Flow Cytometry**[J]. Natural Products and Bioprospecting, 2014, 4(1): 27-35.
[6]	Ponnambalam SUBHASHINI, Elangovan DILIPAN, Thirunavukkarasu THANGARADJOU, Jutta PAPENBROCK. Bioactive natural products from marine angiosperms: abundance and functions[J]. Natural Products and Bioprospecting, 2013, 3(4): 129-136.
[7]	Mohammad Mijanur RAHMAN, Md. Asaduzzaman KHAN. Anti-cancer potential of South Asian plants[J]. Natural Products and Bioprospecting, 2013, 3(3): 74-88.
[8]	Steffen WÖLL, Sun Hee KIM, Henry Johannes GRETEN, Thomas EFFERTH. Animal plant warfare and secondary metabolite evolution[J]. Natural Products and Bioprospecting, 2013, 3(1): 1-7.
[9]	Xu DENG, Ling-Mei KONG, Yu ZHAO, Juan HE, Li-Yan PENG, Yan LI, Qin-Shi ZHAO. Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products[J]. Natural Products and Bioprospecting, 2012, 2(5): 210-216.
[10]	Hassan KHALID, Wail Elsadig ABDALLA, Haider ABDELGADIR, Till OPATZ, Thomas EFFERTH. Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan[J]. Natural Products and Bioprospecting, 2012, 2(3): 92-103.

Viewed

Full text

Abstract

Cited

Shared

Discussed